Chemophase
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Superficial Bladder Cancer
Conditions
Superficial Bladder Cancer
Trial Timeline
Oct 1, 2008 → Aug 1, 2009
NCT ID
NCT00782587About Chemophase
Chemophase is a phase 1 stage product being developed by Halozyme Therapeutics for Superficial Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00782587. Target conditions include Superficial Bladder Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00782587 | Phase 1 | Completed |
Competing Products
11 competing products in Superficial Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | enGene | Phase 1/2 | 33 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Diclofenac gel | Novartis | Approved | 85 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Dalteparin sodium injection | Pfizer | Approved | 84 |
| Rivaroxaban + Fondaparinux | Bayer | Phase 3 | 74 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 69 |
| EscharEx 5% (EX-02 formulation) | MediWound | Phase 1/2 | 33 |
Other Products from Halozyme Therapeutics
Commercial Hylenex® recombinant (hyaluronidase human injection) + Precommercial Hylenex recombinant (hyaluronidase human injection) + Insulin lispro + Insulin aspart + Insulin glulisineApproved
82
HylenexApproved
82
large protein moleculeApproved
82
Sham Injection + Recombinant human hyaluronidase PH20 + Insulin aspart + Insulin lisproApproved
82
Rapid Acting insulin with pre-treatment of rHuPH20Approved
82